Meeting
2018 Genitourinary Cancers Symposium
Adjuvant antiangiogenic agents in post-nephrectomy renal cell carcinoma (RCC): A systematic review and meta-analysis.
Authors
Mohamad Bassam Sonbol
Mayo Clinic, Phoenix, AZ
Mohamad Bassam Sonbol , Talal Hilal , Belal Firwana , Thai Huu Ho , Zhen Wang , Richard Wayne Joseph
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 689)
DOI
10.1200/JCO.2018.36.6_suppl.689
Abstract #
689
Poster Bd #
K18
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Meta-analysis of randomized clinical trials (RCT) for the adjuvant treatment of renal cell carcinoma (RCC) with vascular endothelial growth factor receptor tyrosine-kinase inhibitors (VEGFR TKIs).
First Author: Daniel Vargas Almeida
Poster
2020 Genitourinary Cancers Symposium
Adjuvant therapy in high-risk renal cell cancer: A systematic review and cumulative meta-analysis.
First Author: Rabbia Siddiqi
Poster
2018 Genitourinary Cancers Symposium
Meta-analysis of randomized clinical trials (RCT) for the adjuvant treatment of high-risk clear cell renal carcinoma (RCC) with vascular endothelial growth factor receptor tyrosine-kinase inhibitors (VEGFR TKIs).
First Author: Daniel Vargas Almeida
Poster
2024 ASCO Genitourinary Cancers Symposium
Pembrolizumab plus lenvatinib (P+L) versus alternate therapies in first-line (1L) for advanced renal cell carcinoma (aRCC): A network meta-analysis (NMA).
First Author: Kevin Yan